Skip to main content

Table 3 Physiologic and Subjective Measures – Summary of Peak Changes (Mean ± SD for 12 Subjects)

From: A Phase 1 Trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion

  Session 1 Session 2
Measures Peak
Mean ± SD
Peak Time
(Hr Postdose)
Peak
Mean ± SD
Peak Time
(Hr Postdose)
Physiologic Measures     
Systolic Blood Pressure (mmHg) 17 ± 8 2.2 ± 1.9 17 ± 9 1.9 ± 1.7
Diastolic Blood Pressure (mmHg) 10 ± 5 2.8 ± 2.4 12 ± 6 2 ± 2
Heart Rate (beats/min) 26 ± 10 0.8 ± 0.9 27 ± 12 0.9 ± 1.7
Rate Pressure Product (SBP*HR) 4224 ± 1638 1.4 ± 1.5 4437 ± 2333 0.9 ± 1.6
Respiration Rate (inhal/min) 3.8 ± 4.0 0.9 ± 1.3 3.8 ± 3.6 0.4 ± 0.3
Skin Temperature (°C) -5.4 ± 2.7 0.8 ± 0.4 -5 ± 3.2 1.0 ± 1.2
Core Temperature (°C) 0.7 ± 0.2 4.5 ± 1.6 0.7 ± 0.5 4.2 ± 1.9
Subjective Measures     
Global Intoxication (0–100) 57 ± 27 0.7 ± 1 53 ± 23 0.6 ± 0.9
Cocaine Craving (0–100) 33 ± 25 1.1 ± 1.3 20 ± 21 0.6 ± 0.7
Good Drug Effect (0–100) 66 ± 23 0.9 ± 1.5 60 ± 21 1 ± 1.3
Bad Drug Effect(0–100) 46 ± 31 1.9 ± 2.3 55 ± 25 1.4 ± 1.9
POMS Scales     
Tension (0–28) 7.5 ± 6.1 1 ± 0 4.8 ± 3.9 1 ± 0
Depression (0–64) 3 ± 6.5 3 ± 0 1.5 ± 2.4 3 ± 0
Anger (0–28) 2.8 ± 6.4 6 ± 0 -2.1 ± 5.7* 6 ± 0
Vigor (0–32) -3.6 ± 3.4 6 ± 0 -3.9 ± 6.1 6 ± 0
Confusion (0–20) 2.5 ± 2.8 6 ± 0 2.7 ± 4.7 3 ± 0
Fatigue (0–28) 5.9 ± 5.9 6 ± 0 2.8 ± 5.3 6 ± 0
  1. * Significantly different from Session 1 (p < 0.03).
  2. Session 1: First cocaine infusion, performed on day 1, before selegiline administration.
  3. Session 2: Second cocaine infusion, performed on day 11, following one week of selegiline administration by STS patch (6 mg/24 hours). Infusion began 2 hours after application of the selegiline daily patch.